

1 **Differential Causal Effects of Type 1 and Type 2 Diabetes on Osteomyelitis Risk:**
2 **Insights from Mendelian Randomization Analysis**

3 YanHui Li¹, MD; Chuanyang Zhou², MD; Liming Yang³, MD; Lei Tan^{2,*}, MD
4 ¹Department of Cardiology and Echocardiography, Ultrasound Diagnostic Center,
5 the First Hospital of Jilin University, Changchun, 130021, China
6 ²Department of OrthopedicsTrauma, Orthopaedic Center, the First Hospital of
7 Jilin University, Changchun, 130021, China
8 ³Department of Cardiac Surgery, the First Hospital of Jilin University,
9 Changchun, 130021, China

10
11
12
13
14
15
16
17
18
19
20
21

Running title: Causal Effects of Diabetes on Osteomyelitis Risk

Author for correspondence:

Lei Tan, MD

Department of Orthopedic Trauma, Orthopaedic Center, The First Hospital of
Jilin University; No. 71 Xinmin Street, Changchun, Jilin, China; tanlei@jlu.edu.cn

E-mail addresses:

YanHui Li: yan_hui@jlu.edu.cn

Chuanyang Zhou: cyzhou22@mails.jlu.edu.cn

Liming Yang: yanglmjdy@jlu.edu.cn

Lei Tan: tanlei@jlu.edu.cn

1 **Abstract:**

2

3 Background: Osteomyelitis (OM) poses a significant clinical challenge, especially
4 among individuals with diabetes mellitus (DM). While both type 1 diabetes mellitus
5 (T1DM) and type 2 diabetes mellitus (T2DM) have been linked to an elevated risk of
6 OM, the precise causal relationships remain uncertain.

7

8 Methods: We conducted Mendelian randomization (MR) analyses using summary
9 statistics from genome-wide association studies (GWAS) to explore the causal effects
10 of T1DM, T2DM, their complications, and glycemic traits on OM risk. The study
11 utilized the inverse variance weighted (IVW) method, along with weighted median
12 and MR-Egger for causal estimation, and performed various sensitivity analyses to
13 ensure robustness. Multivariable MR (MVMR) analysis assessed direct effects, while
14 two-step mediation MR analyses investigated the mediating role of DM between
15 rheumatoid arthritis (RA) and OM.

16

17 Results: The MR analysis unveiled distinct causal effects of T1DM and T2DM on
18 OM risk. Genetically determined T2DM, rather than its complications, significantly
19 increased OM risk (primary dataset: IVW: OR = 1.13, 95% CI 1.056–1.209, $p =$
20 $4E-04$; validation dataset: IVW: OR = 1.317, 95% CI 1.14–1.522, $p = 2E-04$;
21 Meta-analysis: OR=1.206; 95% CI 1.037–1.402; $p=0.014$), with no observable
22 heterogeneity or horizontal pleiotropy. MVMR analysis confirmed the robustness of
23 the causal association between T2DM and OM, even after adjusting for potential
24 confounders such as body mass index. Conversely, T1DM and its complications
25 showed no significant causal link with OM in either the primary dataset (IVW: $p =$
26 0.071), the validation dataset (IVW: $p = 0.276$), or the meta-analysis (IVW: $p = 0.242$).
27 Additionally, there was no robust evidence supporting the causal risk of glycemic
28 traits on OM. Mediation MR analysis underscored T2DM as a pivotal contributor to
29 the differential effects of RA on OM.

30

31 Conclusions: Mendelian randomization analysis provides compelling evidence of a
32 significant causal relationship between genetically determined T2DM and increased
33 OM risk, while T1DM exhibits distinct causal effects. Additionally, our findings
34 highlight the role of T2DM in mediating the association between RA and OM. Further
35 research is warranted to elucidate the underlying mechanisms and guide targeted
36 interventions for OM prevention and management in diabetic populations.

37

38

39 **Introduction**

40 Osteomyelitis (OM), a bone infection, can occur via contiguous spread from

1 surrounding tissues, direct bone trauma, or hematogenous dissemination. It poses a
2 considerable healthcare burden, with a prevalence of 22 cases per 100,000
3 person-years in the United States, rising over time, especially among the elderly and
4 those with diabetes mellitus (DM)¹. Challenges in treatment include pathogen
5 identification, bone destruction and repair complexities, and disease recurrence,
6 resulting in prolonged treatment and poorer prognoses².

7
8 Diabetes mellitus, affecting nearly 500 million individuals worldwide and projected to
9 increase by 51% by 2045, poses a significant global health challenge³. Type 1 diabetes
10 mellitus (T1DM) and type 2 diabetes mellitus (T2DM) are the primary forms, each
11 with distinct pathophysiological mechanisms. While T1DM stems from autoimmune
12 destruction of pancreatic beta cells, T2DM involves insulin resistance and impaired
13 insulin secretion⁴. Although observational studies have linked DM to a higher risk of
14 OM^{5,6}, uncertainties persist regarding causal relationships and potential mediators due
15 to confounding factors and biases in existing research. Moreover, limited studies have
16 explored the differing impacts of diabetes subtypes on OM risk.

17
18 Clinical studies have established a link between Rheumatoid Arthritis (RA) and
19 heightened susceptibility to OM, attributed to chronic inflammation^{7,8}. RA is also
20 associated with diabetes due to a vicious circle perpetuated by glucose derangement
21 and inflammatory mediators.^{9,10}. Given the shared risk profile of RA with both
22 diabetes and OM, we employed mediation MR analysis to investigate the mediating
23 role of DM between RA and OM.


24
25 Randomized controlled trials (RCTs) are ideal for understanding causality, but their
26 implementation is impractical due to ethical and complex relations between OM and
27 diabetes. MR offers an alternative using genetic variation as a proxy for exposure,
28 mitigating bias¹¹. This method mirrors RCTs, validating causal relationships while
29 reducing biases. Moreover, MR elucidates independent causal pathways and potential
30 mediators linking DM and OM.

31
32 In this study, we utilized univariable MR (UVMR) analyses to evaluate the impact of
33 T1DM, T2DM, and their complications on OM risk, as well as to explore the
34 association between glycemic traits and OM. Multivariable MR (MVMR) analysis
35 was conducted to assess direct effects by adjusting for potential confounders.
36 Additionally, two-step mediation MR analyses were employed to explore DM's
37 mediating role between RA, and OM.

38 39 **Methods**

40 1. Study design and data sources

1 In this study, we employed UVMR, UVMR and two-step mediation MR analyses to
 2 examine the causal effects of T1DM, T2DM, their complications and glycemic traits
 3 on OM risk, and to explore DM's mediating role between RA and OM. Throughout
 4 the study, we rigorously adhered to three core assumptions ensured the validity of our
 5 results: (1) establishing a reliable association between genetic variants and the risk
 6 factor; (2) confirming no association between genetic variants and confounders; and
 7 (3) ensuring genetic variants solely influence the outcome through the risk factors. A
 8 comprehensive study design flowchart is provided in Figure 1.
 9 Our study utilized the largest and most recent publicly available summary statistics
 10 from multiple genome-wide association studies (GWAS) sources, including the
 11 FinnGen database, the UK Biobank (UKBB) database, and other large consortia. To
 12 prevent overlap, we carefully selected exposure factors, designating T1DM and
 13 T2DM data from FinnGen, and OM data from the UKBB as the primary dataset. DM
 14 data from non-FinnGen sources and additional data from FinnGen were designated as
 15 the validation dataset. To ensure robustness, we conducted a meta-analysis of results
 16 from these datasets. Adherence to the STROBE-MR (Strengthening the Reporting of
 17 Mendelian Randomization Studies) guidelines was maintained throughout the study¹².
 18 Detailed information on the GWAS data used in this study is provided in
 19 Supplementary Tables 1.
 20



21
 22 Figure 1. Flowchart of the study design. GWAS, genome-wide association studies;
 23 T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; RA, rheumatoid
 24 arthritis; OM, osteomyelitis; UVMR, Univariable MR; MVMR, multivariable
 25 mendelian randomization; BMI, body mass index; UKBB, United Kingdom Biobank;
 26 IVs, instrument variables.
 27

1 2. Genetic association datasets

2 GWAS data for T1DM and T1DM with complications

3 Type 1 Diabetes (T1DM) genetic instruments were selected from two GWAS Studies.
4 THE Non-UKBB One is based on 5,928 cases and 183,185 controls of European
5 ancestry from the FinnGen database as the primary source. Validation (Non- FinnGen)
6 was conducted meta-analysis using data from Onengut-Gumuscu et al.'s study, which
7 included 6,683 T1DM cases from the UK Genetic Resource Investigating Diabetes
8 cohort and control samples (N=12,173) from four additional cohorts, all reporting
9 European ancestry¹³. T1DM with complications dataset obtained from FinnGen
10 database¹⁴.Detailed information on single nucleotide polymorphisms (SNPs) used in
11 this study is presented in Supplementary Tables S4 and S6.

12

13 GWAS data for T2DM and T2DM with complications

14 The genetic instruments for T2DM were derived from FinnGen database comprising
15 32,469 cases and 183,185 controls of European ancestry as the primary source
16 (Non-UKBB). For validation (Non-FinnGen), we utilized data from the GWAS
17 meta-analysis study by Xue A et al., which included a sample of 61,714 cases and
18 593,952 controls with T2DM. This study combined three GWAS datasets of European
19 ancestry, including UKBB, representing the vast majority (99.4%) of individuals of
20 European ancestry¹⁵. T2DM with complications dataset obtained from FinnGen
21 database¹⁴. Detailed information regarding the SNPs used can be found in
22 Supplementary Tables S6 and S10.

23

24 GWAS data for Hyperglycemia traits

25 SNPs were chosen from a GWAS meta-analysis by Chen et al., involving 151,013
26 European individuals for fasting insulin, up to 200,622 participants for fasting glucose
27 ¹⁶. The GWAS summary statistics for HbA1c levels were obtained from Within family
28 GWAS consortium, which included 45,734 participants of European ancestry. All
29 participants had European ancestry, and there was no overlap with the outcome data.
30 Detailed SNP information is available in Supplementary Tables S12, 14 and 16.

31

32 GWAS data for Body mass index (BMI)

33 The GWAS summary statistics for MVMR (BMI) were sourced from Within family
34 GWAS consortium, involving 99,998 European participants. There was no overlap
35 between this dataset and other exposures and outcomes considered in our study.

36

37 GWAS data for RA

38 The GWAS summary statistics for RA were obtained from Eyre S et al., which
39 included 13,838 cases and 33,742 controls of European ancestry¹⁷. There was no
40 overlap between this dataset and all exposures and outcomes considered in our study.

1 Supplementary Table 18 provides details of the traits involved in this analysis.

2

3 GWAS data for Outcomes

4 The study outcome is OM, defined as inflammation of bone and its structures due to
5 pyogenic bacterial infection. We analyzed the associations between selected
6 instruments and OM using summary GWAS data from the UK Biobank (4,836 cases,
7 481,648 controls) as the primary source. Validation was performed using FinnGen
8 data (842 cases, 209,575 controls), all of European ancestry.

9

10 3.Genetic Instrument Selection

11 For genetic instrument selection, we established a genome-wide significance
12 threshold. SNPs with a P-value less than 5×10^{-8} were considered significant for
13 T1DM, T2DM, glycemc traits, BMI and RA. Since only few SNPs were identified
14 for part of complications of DM when they were as the exposure, a higher cutoff
15 ($p < 1e-6$) was chosen. Variants meeting these criteria were then clumped for
16 linkage disequilibrium (LD) using a distance window of 10,000 kB and an $r^2 < 0.01$.

17 To avoid the risk of weak instrumental bias, the F statistic was performed to evaluate
18 the strength of the IV. When $F > 10$, the association between the IV and exposures
19 was deemed to be sufficiently robust, thereby safeguarding the results of the MR
20 analysis against potential weak instrumental bias. The PhenoScanner
21 (<http://www.phenoscaner.medschl.cam.ac.uk/>) was introduced to identify and
22 remove SNPs with potential associations with confounding factors that might violate
23 the independence assumption¹⁸. After several rounds of rigorous filtering, a set of
24 eligible instrumental variables for the subsequent MR analysis were obtained.
25 Summary of the instrument variables used in this study is presented in Supplementary
26 Tables S2.

27

28 4. Statistical analysis

29 We employed the "TwoSampleMR"²², "MendelianRandomization"²³ and
30 "MR-PRESSO"²⁴ packages for UVMR, MVMR, and Mediation MR analyses,
31 including sensitivity tests. Causal estimates were expressed as odds ratios (ORs) with
32 95% confidence intervals (CIs). Statistical analyses were conducted using R software
33 version 4.3.2 (The R Foundation for Statistical Computing).

34

35 UVMR analysis

36 Causal effects were estimated using the random-effects inverse variance weighted
37 (IVW) method¹⁹. To ensure unbiased estimates, MR analyses were also conducted
38 using four alternative methods (MR Egger, Simple mode, Weighted median, and
39 Weighted mode). A causal effect was considered suggested if the IVW p-value was

1 less than 0.05. Moreover, a causal effect was deemed significant if the IVW p-value
2 fell below the Bonferroni-corrected threshold ($p < 0.05/21 = 0.002$) for primary
3 datasets and ($p < 0.05/7 = 0.007$) for validation datasets, coupled with consistent
4 directionality in the weighted median and MR-Egger results.

5

6 MVMR

7 The DM and BMI shared genetic risk factors²⁰. To mitigate the confounding influence
8 of BMI on DM, MVMR analysis adjusting for BMI was performed. For the
9 significant causal associations in the univariable MR analysis, the MVMR analysis
10 was performed using the MVMR-IVW method, aiming to adjust for potential
11 confounding factors BMI²¹.

12

13 Mediation MR analysis

14 Clinical studies indicate that RA is associated with an increased risk of OM⁹. To
15 explore whether DM mediates this association, we conducted two-step mediation MR
16 analysis, assessing three key estimates: (i) the total effect of RA on OM (β_{all}); (ii)
17 the direct effect of RA on DM (β_1); and (iii) the direct effect of DM on OM (β_2).
18 Significance was determined by IVW p-values ($p < 0.05$), with mediation effect
19 proportions estimated using the delta method. The mediation effect is calculated as β_1
20 * β_2 . The proportion of the mediation effect was estimated as the total causal effect of
21 β_{all} divided by the mediation effect. We performed two-step mediation MR analyses
22 in both primary and validation datasets to ensure result reliability and compared them
23 for consistency.

24

25 Sensitivity analyses

26 Sensitivity analyses were performed to address horizontal pleiotropy and
27 heterogeneity. We utilized weighted median, MR-Egger, and MR-PRESSO methods
28 to verify assumptions and assess robustness, identifying potential horizontal
29 pleiotropy. The weighted median model provides consistent estimates when over half
30 of the weights are from valid IVs²⁵. MR-Egger regression detects horizontal
31 pleiotropy and corrects for it, with its intercept term indicating unbalanced directional
32 pleiotropy ($p < 0.05$)²⁶. MR-PRESSO identifies and corrects outliers, providing
33 outlier-corrected estimates. The MR-PRESSO distortion test compares estimation
34 differences before and after outlier removal. Cochran's Q test evaluates heterogeneity
35 among SNPs for exposure and confirms consistency between MR assumptions and
36 analyses ($p < 0.05$)²⁴. Credible causal inference requires consistent directionality
37 across the three methods and the absence of horizontal pleiotropic effects.

38

39 Results

40 1.NO Causal effects of T1DM on OM

1 The causal effect of T1DM on OM was not supported in either the primary dataset
 2 (IVW: $p = 0.071$), the validation dataset (IVW: $p = 0.276$), or the meta-analysis (IVW:
 3 $p = 0.242$). Sensitivity analyses revealed consistent results with no evidence of
 4 horizontal pleiotropy (MR-Egger intercept $p = 0.521$; $p = 0.967$) and no heterogeneity
 5 (Cochran's Q statistic: $p = 0.089$; $p = 0.244$) for the primary and validation datasets,
 6 respectively. No outliers were found in the MR-PRESSO test. To further address the
 7 potential influence of confounding factors and level pleiotropy, we conducted MVMR.
 8 After controlling for BMI, no statistical significance remained between T1DM and
 9 OM (Figure 2; Supplementary Table S3). Leave-one-out and scatter plots are provided
 10 in Supplementary Figures 1-4.

11 To explore the relationship between different T1DM subgroups and OM, we analyzed
 12 data from the comprehensive FinnGen database, known for its coverage of T1DM
 13 complications. Our analysis revealed no causal correlations between either T1DM
 14 without complications or T1DM with complications and OM (IVW: $p = 0.478$;
 15 $p = 0.777$, respectively). Further subgroup analyses within T1DM with
 16 complications showed no causal links with OM. Specifically, IVW P values for OM
 17 were 0.885 for T1DM with coma, 0.843 for T1DM with ketoacidosis, 0.770 for
 18 T1DM with ophthalmic complications, 0.978 for T1DM with renal complications,
 19 0.197 for T1DM with peripheral circulatory complications, and 0.345 for T1DM with
 20 neurological complications. No evidence of horizontal pleiotropy or heterogeneity
 21 was found in these MR analyses. (Figure 2; Supplementary Table S5).

Exposure	Outcome	nsnp	method	OR(95% CI)	pval	MVMR_pval	H_pval	P_pval
T1DM(FinnGen)	OM(UKBB)	58	IVW	1.031 (0.997 to 1.066)	0.071	0.302	0.089	
			MR Egger	1.046 (0.991 to 1.105)	0.127		0.521	
			Weighted median	1.044 (1.008 to 1.082)	0.016			
T1DM	OM(FinnGen)	36	IVW	1.054 (0.959 to 1.159)	0.276	0.144	0.244	
			MR Egger	1.051 (0.885 to 1.248)	0.575		0.967	
			Weighted median	1.008 (0.866 to 1.174)	0.916			
Meta								
T1DM	OM		IVW	1.153 (0.908 to 1.465)	0.242			
			MR Egger	1.166 (0.871 to 1.559)	0.302			
			Weighted median	1.193 (0.881 to 1.615)	0.253			
T1DM without complications	OM(UKBB)	15	IVW	0.983 (0.937 to 1.031)	0.487	0.43	0.161	
			MR Egger	0.988 (0.896 to 1.090)	0.815		0.907	
			Weighted median	1.012 (0.953 to 1.075)	0.697			
T1DM with multiple complications	OM(UKBB)	15	IVW	1.004 (0.975 to 1.035)	0.777	0.734	0.242	
			MR Egger	1.013 (0.968 to 1.059)	0.594		0.631	
			Weighted median	1.017 (0.982 to 1.053)	0.352			
coma	OM(UKBB)	9	IVW	1.002 (0.973 to 1.032)	0.885	0.849	0.155	
			MR Egger	1.013 (0.964 to 1.065)	0.626		0.606	
			Weighted median	1.012 (0.982 to 1.043)	0.450			
ketoacidosis	OM(UKBB)	10	IVW	1.003 (0.972 to 1.035)	0.843	0.772	0.063	
			MR Egger	1.017 (0.969 to 1.068)	0.517		0.486	
			Weighted median	1.011 (0.982 to 1.042)	0.450			
ophthalmic complications	OM(UKBB)	16	IVW	0.995 (0.959 to 1.031)	0.770	0.995	0.069	
			MR Egger	1.028 (0.973 to 1.086)	0.340		0.147	
			Weighted median	1.002 (0.964 to 1.042)	0.903			
renal complication	OM(UKBB)	7	IVW	1.000 (0.971 to 1.031)	0.978	0.801	0.238	
			MR Egger	1.030 (0.992 to 1.069)	0.182		0.086	
			Weighted median	1.013 (0.983 to 1.045)	0.404			
peripheral circulatory complications	OM(UKBB)	3	IVW	1.018 (0.991 to 1.045)	0.197	0.177	0.58	
			MR Egger	1.020 (0.937 to 1.111)	0.725		0.963	
			Weighted median	1.017 (0.989 to 1.047)	0.237			
neurological complications	OM(UKBB)	9	IVW	1.016 (0.983 to 1.051)	0.345	0.424	0.35	
			MR Egger	1.049 (0.969 to 1.136)	0.275		0.412	
			Weighted median	1.035 (0.993 to 1.078)	0.107			

22

0.7 1 1.3 1.6 1.9

1 Figure. 2. Genetically predicted type 1 diabetes and its complications: associations
2 with osteomyelitis. T1DM, type 1 diabetes mellitus; OM, osteomyelitis; UVMR,
3 Univariable MR; MVMR, multivariable mendelian randomization; OR, odds ratio; CI,
4 confidence interval; UKBB, United Kingdom Biobank; IVW, Inverse Variance
5 Weighted; H, Heterogeneity; P, Pleiotropy. p -values (IVW) ≤ 0.05 was considered
6 suggested different. The Bonferroni-corrected results of the p -values (IVW) in each
7 group remained consistent with the uncorrected results.

8


9 2. Causal effects of T2DM on OM

10 Using IVs for T2DM, we found evidence linking genetically predicted T2DM to
11 increased OM risk (primary dataset: IVW: OR = 1.13, 95% CI 1.056–1.209, $p =$
12 4.20E-04; validation dataset: IVW: OR = 1.317, 95% CI 1.14–1.522, $p = 0.007$;
13 Meta-analysis: OR 1.203; 95% CI 1.038–1.395; $p = 1.85E-04$) (Figure 2). Furthermore,
14 after Bonferroni correction, the results remained statistically significant. The three
15 MR methods showed consistent directions. After MVMR analysis controlling for BMI,
16 statistical significance remained between T2DM and OM (Figure 3; Supplementary
17 Table S7). No outliers were detected by MR-PRESSO, and no heterogeneity was
18 observed by Cochran's Q test. MR-Egger intercept tests found no horizontal
19 pleiotropy. Leave-one-out analysis showed consistent T2DM results (Fig. 2).
20 Leave-one-out and scatter plots are provided in Supplementary Figures 5-8.

21 Using GWAS data for T2DM complications from the FinnGen database, we initially
22 observed suggested causal correlations between both T2DM without complications
23 and T2DM with multiple complications and OM (IVW: OR 1.128; 95% CI
24 1.033–1.232; $p = 0.008$; OR 1.086; 95% CI 1.109–1.158; $p = 0.011$),
25 respectively. However, after multiple testing correction, these causal correlations
26 disappeared. Furthermore, analyses for T2DM with other complications revealed no
27 significant causal correlations with OM. Specifically, IVW-P values for OM were
28 0.164 for T2DM with coma, 0.349 for T2DM with ketoacidosis, 0.215 for T2DM with
29 ophthalmic complications, and 0.053 for T2DM with peripheral circulatory
30 complications. These MR analyses showed no evidence of horizontal pleiotropy or
31 heterogeneity (Figure 3; Supplementary Table S9). Insufficient genetic instruments
32 were available for MR analyses of other T2DM-related complications.

33

34 The findings suggest that genetically predicted T2DM, rather than T2DM with
35 complications, is a risk factor for OM.



1
2 Figure. 3. Genetically predicted type 2 diabetes and its complications: associations
3 with osteomyelitis. T2DM, type 2 diabetes mellitus; OM, osteomyelitis; UVMR,
4 Univariable MR; MVMR, multivariable mendelian randomization; OR, odds ratio; CI,
5 confidence interval; UKBB, United Kingdom Biobank; IVW, Inverse Variance
6 Weighted; H, Heterogeneity; P, Pleiotropy. The IVW p-value ($< \alpha 0.05$) was
7 considered a statistically suggested difference. IVW p-values below the
8 Bonferroni-corrected threshold were considered statistically significant.

9 10 3. Inconsistent Causal Effects of Glycemic Traits on OM

11 There was no causal relationship between fasting insulin and OM in either the
12 primary dataset (IVW: $p = 0.566$) or the validation dataset (IVW: $p = 0.463$).
13 However, fasting glucose showed inconsistent effects on OM. In the primary dataset,
14 the IVW analysis yielded a p-value greater than the threshold (IVW: OR = 1.265, 95%
15 CI: 0.972-1.645, $p = 0.08$), while in the validation dataset, the p-value was smaller
16 than the Bonferroni-corrected threshold (IVW: OR = 2.347, 95% CI: 1.276-4.318, $p =$
17 0.006). However, meta-analysis did not support fasting glucose as a risk factor for
18 OM (IVW: $p = 0.11$). Similarly, inconsistent results were observed for HbA1c levels
19 and OM in the primary dataset ($p = 0.29$) and the validation dataset (IVW: $p = 0.04$),
20 with the latter failing the Bonferroni correction for multiple testing. Nevertheless,
21 meta-analysis indicated that HbA1c levels were not associated with an increased risk
22 of OM (IVW: $p = 0.59$). Sensitivity analyses confirmed no evidence of heterogeneity
23 or horizontal pleiotropy (Table 1, Supplementary Tables S11, S13 and S15). These
24 findings suggest that there may be complex relationships between glycemic traits and
25 OM.

Table 1. MR and Sensitivity analysis of Glycemic Traits with the risk of OM

Exposure	Method	OM(UKB)						OM(FinnGen)						Meta				
		nsnp	beta	se	pval	MMR p	H ₂ pval	P _{het} pval	nsnp	beta	se	pval	MMR p	H ₂ pval	P _{het} pval	beta	se	Pval
Fasting insulin	IWV	38	0.14	0.24	0.57	0.50	0.92	0.74	38	0.43	0.59	0.46	0.45	0.44	0.524	0.18	0.22	0.42
	MR Egger		0.37	0.73	0.61					-0.73	1.90	0.70				0.23	0.68	0.74
	Weighted median		0.21	0.33	0.52					0.89	0.86	0.30				0.30	0.31	0.33
Fasting glucose	IWV	63	0.24	0.13	0.08	0.08	0.67	0.76	63	0.85	0.31	6.10E-03	1.20E-03	0.79	0.11	0.48	0.30	0.11
	MR Egger		0.17	0.24	0.49					1.60	0.56	5.86E-03				0.80	0.71	0.26
	Weighted median		0.27	0.20	0.17					1.02	0.48	0.04				0.52	0.35	0.14
HbA1c levels	IWV	29	-0.06	0.06	0.29	0.16	0.61	0.06	25	0.33	0.16	0.04	0.11	0.80	0.61	0.10	0.19	0.59
	MR Egger		-0.26	0.12	0.03					0.48	0.34	0.17				0.04	0.37	0.91
	Weighted median		-0.18	0.09	0.04					0.41	0.24	0.09				0.07	0.29	0.81

Abbreviation: MR Mendelian Randomization; OM osteomyelitis; UKB United Kingdom Biobank; IWV Inverse Variance Weighted; H₂ Heterogeneity; P_{het} Pleiotropy; SNP single nucleotide polymorphism; OR odds ratio.

1
2 **4. T2DM mediates the causal effect of RA on OM**
3 We employed two-step mediation MR analyses in both primary and validation
4 datasets to explore T2DM's mediation between RA, and OM. RA was associated with
5 increased OM risk (IVW: OR = 1.058, 95% CI 1.005–1.114, P = 0.031), with a
6 25.8% mediation effect (95% CI 9.0%–42.5%) in the primary dataset. Consistent
7 results were observed in the validation dataset analysis, with T2DM mediating 14.5%
8 (95% CI 6.1%–23.0%) of the RA-OM relationship. No heterogeneity or horizontal
9 pleiotropy was detected in any analysis (Table 2; Supplementary Table 17).

Table 2. Mediation effect of T2DM in the association between RA and OM

Exposure	Mediator	Outcome	Dataset	Total effect β _{all}			Direct effect β ₁			Direct effect β ₂			Mediation effect	
				beta	se	P	beta	se	P	beta	se	P	Effect size (95% CI)	Proportion % (95% CI)
RA	T2DM	OM	Primary	0.06	0.03	3.14E-02	0.12	0.02	4.91E-07	0.12	0.03	4.20E-04	0.014(0.005-0.024)	25.8(9.0-42.5)
			Validation	0.18	0.05	5.34E-04	0.09	0.01	7.67E-17	0.28	0.07	1.85E-04	0.026(0.011-0.041)	14.5(6.1-23.0)

Abbreviation: MR Mendelian Randomization; T2DM type 2 diabetes mellitus; OM osteomyelitis; RA Rheumatoid arthritis; CR odds ratio.
β_{all}: exposure to outcome (IVW/MR)
β₁: exposure to mediator (IVW/MR)
β₂: mediator to outcome (IVW/MR)

10

11 Discussion

12 Our MR study revealed distinct causal effects of T1DM and T2DM on OM risk.
13 Specifically, T2DM showed a significant association with increased OM risk, while
14 T1DM and its complications did not exhibit a causal relationship with OM.
15 Additionally, glycemic traits (fasting insulin, fasting glucose, and HbA1c) showed
16 inconsistent effects on OM. Furthermore, we identified that T2DM mediates the
17 causal effect of RA on OM. These findings deepen our understanding of the differing
18 roles of T1DM and T2DM in OM development and provide avenues for further
19 mechanistic investigation.

20

21 The discovery that that T1DM and its complications did not exhibit a causal
22 association with OM challenges our conventional understanding and contradicts some
23 previous study findings.^{27–29} Traditionally, diabetes, including both T1DM and
24 T2DM, has been linked to an elevated risk of various infection complications, such as
25 OM. Moreover, individuals with diabetes face a higher mortality risk from infections
26 compared to the general population, with T1DM patients particularly susceptible³⁰.
27 However, our Mendelian randomization analysis, which provides more robust causal
28 inference compared to observational studies, suggests otherwise. This unexpected

1 result prompts a reevaluation of the assumed causal relationship between T1DM and
2 OM. One possible interpretation could involve the complex interplay between
3 diabetes subtypes and their respective pathophysiological mechanisms. While T2DM
4 is commonly associated with metabolic abnormalities and chronic inflammation, the
5 etiology of T1DM involves autoimmune destruction of pancreatic beta cells. It is
6 plausible that the mechanisms underlying T1DM may not directly contribute to the
7 development of OM, as observed in our study. Another explanation for this
8 discrepancy could be the differences in study design and inherent biases between
9 observational studies and Mendelian randomization. Observational studies are limited
10 to establishing associations and are susceptible to confounding factors, reverse
11 causation, and measurement errors, which may lead to spurious associations. In
12 contrast, Mendelian randomization leverages genetic variants as instrumental
13 variables to mimic the random assignment of exposures, thereby reducing bias and
14 providing more reliable causal estimates³¹.

15
16 The finding that T2DM is significantly associated with increased OM risk aligns with
17 previous clinical studies^{1,5,6}. However, our analysis reveals an unexpected causal
18 relationship between glycemic traits and OM risk. The absence of associations with
19 fasting insulin and HbA1c implies that insulin and HbA1c levels may not contribute
20 to OM risk. Inconsistent causal effects of fasting glucose were observed between the
21 primary dataset and validation dataset, and meta-analysis did not support fasting
22 glucose as a risk factor for OM. Therefore, T2DM may influence OM risk through
23 alternative mechanisms beyond high blood sugar, such as immune response
24 dysfunction³² or metabolic disturbances³³. These findings emphasize the need for
25 further research to elucidate the specific pathways through which T2DM affects OM
26 risk. Additionally, they underscore the importance of comprehensive risk assessment
27 in diabetic patients, beyond glycemic control alone.

28
29 Previous research has established RA as a common risk factor for both T2DM and
30 OM^{7,9,10}. Our study further investigated their associations with T2DM and OM risk,
31 revealing the extent to which T2DM mediates RA's causal effect on OM. These
32 findings underscore the importance of addressing RA to prevent OM and highlight
33 T2DM's role in connecting RA with OM. Such insights have significant clinical
34 implications, suggesting targeted interventions for diabetic patients with RA to
35 mitigate their heightened susceptibility to OM, particularly those requiring orthopedic
36 procedures like fracture fixation or joint replacement. Strategies focusing on
37 optimizing glycemic control and managing inflammation in this patient population
38 may help reduce the risk of OM.

39
40 Our study reveals distinct causal effects of T1DM and T2DM on OM risk,

1 underscoring the need for tailored disease management. Further validation is essential
2 for a comprehensive understanding of these findings. The observed differences in OM
3 risk between T1DM and T2DM warrant further investigation into underlying
4 pathophysiological heterogeneity. Future research should focus on identifying
5 biomarkers to stratify diabetic patients based on their susceptibility to OM and related
6 complications. Additionally, our findings suggest potential drug repurposing for OM
7 management among diabetic patients, emphasizing the importance of clinical trials to
8 validate efficacy and safety profiles. While our study provides valuable insights,
9 prospective clinical studies are needed to validate our findings and improve clinical
10 outcomes for diabetic patients.

11
12 Our study boasts several strengths. Firstly, it pioneers the investigation into the causal
13 link between DM and OM using MR approaches. Notably, it marks the inaugural
14 documentation of the absence of a causal effect of T1DM on OM. Secondly, we
15 employ MR techniques to mitigate potential confounding biases and ensure reliable
16 causal inferences. Thirdly, our use of GWAS data primarily from European ancestry
17 populations minimizes population stratification bias. all outcomes underwent rigorous
18 validation through various sensitivity analyses, including inverse-variance weighted
19 (IVW), MR-Egger, MR-PRESSO, leave-one-out analysis, and MVMR, with multiple
20 testing corrections applied. Furthermore, consistent results across different datasets
21 and meta-analysis underscored the robustness of our findings.

22
23 Our study has limitations affecting generalizability and interpretation. Focusing on a
24 single ethnic group restricts broader applicability³⁴. Replicating in diverse cohorts is
25 necessary. Reliance on summary statistics from GWAS may introduce
26 misclassification bias. Additionally, while benefiting from large-scale data, our
27 sample size may be insufficient to detect small effect sizes or rare variants. Potential
28 pleiotropy in Mendelian randomization analysis and residual confounding remains
29 concerns, despite sensitivity analyses.

30
31 **In conclusion**, our study offers compelling evidence of a significant causal
32 relationship between genetically determined T2DM and heightened risk of OM, while
33 T1DM shows no causal effects. Additionally, our findings highlight the role of T2DM
34 in mediating the association between RA and OM. These insights hold promise for
35 improving clinical outcomes among diabetic individuals and those at risk of OM.

36 **Acknowledgments**

37
38 We want to acknowledge the participants and investigators of the FinnGen study,
39 UK Biobank, and other GWASs included in this study. Without the dedication of these
40 organizations and their members, this article would have been difficult to complete.

1 **Funding**

2 We thank the Jilin Province Science and Technology Development Grant (grant
3 Nos. 20210101452JC and YDZJ202301ZYTS096) for funding this study.

4 **Conflict of Interest**

5 The authors declare that they have no conflicts of interest.

6 **Data Availability Statement**

7 All data generated or analyzed during this study are included in this article and
8 its supplementary information files.

9 **Ethics Statement**

10 Not applicable

11 **Author Contributions:** L.T. conceived the project, designed the study and
12 revised the manuscript.; YH.L. wrote the manuscript; CY.Z. collected data from the
13 public database; L.T., YH.L. and LM.Y. performed the study, and all authors reviewed
14 the manuscript.

15 **Competing interests**

16 The authors declare no competing interests.

17 **Consent for Publication**

18 Not applicable

19 **Abbreviations**

20 T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; OM,
21 osteomyelitis; IVW: Inverse variance weighted; IVs: Instrumental variables; SNPs:
22 Single Nucleotide Polymorphisms; UVMR, Univariable MR; MVMR: Multivariable
23 MR; OR: Odds ratio; CI, confidence interval; GWAS: Genome-Wide Association
24 Study; UKBB, United Kingdom Biobank

25
26 **References**

- 27 1. Kremers, H. M. *et al.* Trends in the epidemiology of osteomyelitis: a
28 population-based study, 1969 to 2009. *J. Bone Joint Surg. Am.* **97**, 837–845 (2015).
29 2. Lew, D. P. & Waldvogel, F. A. Osteomyelitis. *Lancet Lond. Engl.* **364**, 369–379
30 (2004).
31 3. Saeedi, P. *et al.* Global and regional diabetes prevalence estimates for 2019 and
32 projections for 2030 and 2045: Results from the International Diabetes Federation
33 Diabetes Atlas, 9th edition. *Diabetes Res. Clin. Pract.* **157**, 107843 (2019).
34 4. Banday, M. Z., Sameer, A. S. & Nissar, S. Pathophysiology of diabetes: An
35 overview. *Avicenna J. Med.* **10**, 174–188 (2020).
36 5. Al-Mayahi, M. *et al.* Associations of diabetes mellitus with orthopaedic infections.
37 *Infect. Dis. Lond. Engl.* **48**, 70–73 (2016).
38 6. Peng, J. *et al.* Epidemiological, Clinical and Microbiological Characteristics of
39 Patients with Post-Traumatic Osteomyelitis of Limb Fractures in Southwest China: A
40 Hospital-Based Study. *J. Bone Jt. Infect.* **2**, 149–153 (2017).

- 1 7. Jha, Y. & Chaudhary, K. Diagnosis and Treatment Modalities for Osteomyelitis.
2 *Cureus* **14**, e30713.
- 3 8. Al-Ahaideb, A. Septic arthritis in patients with rheumatoid arthritis. *J. Orthop.*
4 *Surg.* **3**, 33 (2008).
- 5 9. Di Muzio, C., Cipriani, P. & Ruscitti, P. Rheumatoid Arthritis Treatment Options
6 and Type 2 Diabetes: Unravelling the Association. *BioDrugs Clin. Immunother.*
7 *Biopharm. Gene Ther.* **36**, 673–685 (2022).
- 8 10. Z, T., J, M., A, V., H, C. & Ah, H. The relationship between rheumatoid arthritis
9 and diabetes mellitus: a systematic review and meta-analysis. *Cardiovasc. Endocrinol.*
10 *Metab.* **10**, (2021).
- 11 11. Sekula, P., Del Greco M, F., Pattaro, C. & Köttgen, A. Mendelian Randomization
12 as an Approach to Assess Causality Using Observational Data. *J. Am. Soc. Nephrol.*
13 *JASN* **27**, 3253–3265 (2016).
- 14 12. Skrivankova, V. W. *et al.* Strengthening the reporting of observational studies in
15 epidemiology using mendelian randomisation (STROBE-MR): explanation and
16 elaboration. *The BMJ* **375**, n2233 (2021).
- 17 13. Onengut-Gumuscu, S. *et al.* Fine mapping of type 1 diabetes susceptibility loci
18 and evidence for colocalization of causal variants with lymphoid gene enhancers. *Nat.*
19 *Genet.* **47**, 381–386 (2015).
- 20 14. Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped
21 isolated population. *Nature* **613**, 508–518 (2023).
- 22 15. Xue, A. *et al.* Genome-wide association analyses identify 143 risk variants and
23 putative regulatory mechanisms for type 2 diabetes. *Nat. Commun.* **9**, 2941 (2018).
- 24 16. Chen, J. *et al.* The trans-ancestral genomic architecture of glycemic traits. *Nat.*
25 *Genet.* **53**, 840–860 (2021).
- 26 17. Eyre, S. *et al.* High-density genetic mapping identifies new susceptibility loci for
27 rheumatoid arthritis. *Nat. Genet.* **44**, 1336–1340 (2012).
- 28 18. Kamat, M. A. *et al.* PhenoScanner V2: an expanded tool for searching human
29 genotype-phenotype associations. *Bioinforma. Oxf. Engl.* **35**, 4851–4853 (2019).
- 30 19. Burgess, S. *et al.* Guidelines for performing Mendelian randomization
31 investigations: update for summer 2023. *Wellcome Open Res.* **4**, 186 (2023).
- 32 20. Carlsson, S., Ahlbom, A., Lichtenstein, P. & Andersson, T. Shared genetic
33 influence of BMI, physical activity and type 2 diabetes: a twin study. *Diabetologia* **56**,
34 1031–1035 (2013).
- 35 21. Mendelian randomization analysis with multiple genetic variants using
36 summarized data - PubMed. <https://pubmed.ncbi.nlm.nih.gov/24114802/>.
- 37 22. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference
38 across the human phenome. *eLife* **7**, e34408.
- 39 23. Yavorska, O. O. & Burgess, S. MendelianRandomization: an R package for
40 performing Mendelian randomization analyses using summarized data. *Int. J.*

- 1 *Epidemiol.* **46**, 1734–1739 (2017).
- 2 24. Verbanck, M., Chen, C.-Y., Neale, B. & Do, R. Detection of widespread
3 horizontal pleiotropy in causal relationships inferred from Mendelian randomization
4 between complex traits and diseases. *Nat. Genet.* **50**, 693–698 (2018).
- 5 25. Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent
6 Estimation in Mendelian Randomization with Some Invalid Instruments Using a
7 Weighted Median Estimator. *Genet. Epidemiol.* **40**, 304–314 (2016).
- 8 26. Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian Randomization
9 Analysis With Multiple Genetic Variants Using Summarized Data. *Genet. Epidemiol.*
10 **37**, 658–665 (2013).
- 11 27. Brown, N. L. *et al.* Bioburden after *Staphylococcus aureus* inoculation in type 1
12 diabetic rats undergoing internal fixation. *Plast. Reconstr. Surg.* **134**, 412e–419e
13 (2014).
- 14 28. Moschovi, M. *et al.* Subacute vertebral osteomyelitis in a child with diabetes
15 mellitus associated with *Fusarium*. *Pediatr. Int. Off. J. Jpn. Pediatr. Soc.* **46**, 740–742
16 (2004).
- 17 29. Caruso, P. *et al.* When amputation is not the end of the challenge: A successful
18 therapy for osteomyelitis and soft tissue infection in a patient with type 1 diabetes. *J.*
19 *Diabetes Investig.* **13**, 209–212 (2022).
- 20 30. Magliano, D. J. *et al.* Excess Risk of Dying From Infectious Causes in Those
21 With Type 1 and Type 2 Diabetes. *Diabetes Care* **38**, 1274–1280 (2015).
- 22 31. Sanderson, E. *et al.* Mendelian randomization. *Nat. Rev. Methods Primer* **2**, 1–21
23 (2022).
- 24 32. Berbudi, A., Rahmadika, N., Tjahjadi, A. I. & Ruslami, R. Type 2 Diabetes and
25 its Impact on the Immune System. *Curr. Diabetes Rev.* **16**, 442–449 (2020).
- 26 33. Daryabor, G., Atashzar, M. R., Kabelitz, D., Meri, S. & Kalantar, K. The Effects
27 of Type 2 Diabetes Mellitus on Organ Metabolism and the Immune System. *Front.*
28 *Immunol.* **11**, 1582 (2020).
- 29 34. Burgess, S., Davies, N. M. & Thompson, S. G. Bias due to participant overlap in
30 two-sample Mendelian randomization. *Genet. Epidemiol.* **40**, 597 (2016).

31

32 **Figure Legends**

33 Figure 1. Flowchart of the study design. GWAS, genome-wide association studies;
34 T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; RA, rheumatoid
35 arthritis; OM, osteomyelitis; UVMR, Univariable MR; MVMR, multivariable
36 mendelian randomization; BMI, body mass index; UKBB, United Kingdom Biobank;
37 IVs, instrument variables.

38 **Figure 2.** Genetically predicted type 1 diabetes and its complications: associations
39 with osteomyelitis. T1DM, type 1 diabetes mellitus; OM, osteomyelitis; UVMR,
40 Univariable MR; MVMR, multivariable mendelian randomization; OR, odds ratio; CI,

1 confidence interval; UKBB, United Kingdom Biobank; IVW, Inverse Variance
2 Weighted; H, Heterogeneity; P, Pleiotropy. p-values (IVW) < 0.05 was considered
3 suggested different. The Bonferroni-corrected results of the p-values (IVW) in each
4 group remained consistent with the uncorrected results.

5 **Figure 3.** Genetically predicted type 2 diabetes and its complications: associations
6 with osteomyelitis. T2DM, type 2 diabetes mellitus; OM, osteomyelitis; UVMR,
7 Univariable MR; MVMR, multivariable mendelian randomization; OR, odds ratio; CI,
8 confidence interval; UKBB, United Kingdom Biobank; IVW, Inverse Variance
9 Weighted; H, Heterogeneity; P, Pleiotropy. The IVW p-value (< 0.05) was
10 considered a statistically suggested difference. IVW p-values below the
11 Bonferroni-corrected threshold were considered statistically significant.